Assessing the Influence of Benign Prostatic Hyperplasia (BPH) on Erectile Dysfunction (ED) among patients in Poland
- PMID: 24578949
- PMCID: PMC3921801
- DOI: 10.5173/ceju.2012.03.art7
Assessing the Influence of Benign Prostatic Hyperplasia (BPH) on Erectile Dysfunction (ED) among patients in Poland
Abstract
Introduction: Erectile dysfunction (ED) and the lower urinary tract symptoms caused by benign prostatic hyperplasia (LUTS/BPH) are highly prevalent among aging men. More data are needed from studies evaluating the impact of LUTS/BPH on ED. This study aimed to assess ED in patients with LUTS/BPH independent of comorbidities.
Material and methods: During 2007 and 2008, we examined 10,932 patients aged 50 to 69 years with LUTS/BPH (IPSS = 8-19 points) using questionnaires: Sex-Score and International Index of Erectile Function 5 (IIEF-5). Patients who used alcohol and/or cigarettes and those with hypertension, diabetes, or hyperlipidemia and cholesterolemia were excluded from meta analyses, which left 4,354 patients with LUTS/BPH without any comorbidity for the analyses. The main survey instruments used were the Sex-Score and IIEF-5.
Results: Regarding sexual coexistence, 1,497 (34.4%) and 2,638 (60.6%) patients considered it very important or important respectively; however, 219(5%) patients reported no sexual activity. After excluding sexually inactive patients, only 1,088 (25%) patients had the ability to obtain an erection during sexual activity always or nearly always. However, that erection was only strong enough to penetrate their partner almost always or most of the time in 218 (5%) and 826 (19%) patients respectively and only 610 (14%) patients were always able to maintain their erection during sexual intercourse. While only 87 (2%) patients had no difficulty maintaining their erection until the completion of intercourse, 174 (4%) and 914 (21%) patients stated that sexual intercourse gave satisfaction nearly always or most of the time respectively.
Conclusions: The impact of ED on patients with LUTS/BPH is evident across domains.
Keywords: International Index of Erectile Function 5; International Prostate Symptom Score; benign prostatic hyperplasia; erectile dysfunction; lower urinary tract symptoms.
Figures







Similar articles
-
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19. J Sex Med. 2013. PMID: 23782459 Clinical Trial.
-
An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.BJU Int. 2008 Jan;101(2):197-202. doi: 10.1111/j.1464-410X.2007.07320.x. Epub 2007 Nov 13. BJU Int. 2008. PMID: 18005205
-
Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.Urol Int. 2008;80(3):296-9. doi: 10.1159/000127345. Epub 2008 May 14. Urol Int. 2008. PMID: 18480635
-
Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.BJU Int. 2005 Jun;95 Suppl 4:12-8. doi: 10.1111/j.1464-410X.2005.05486.x. BJU Int. 2005. PMID: 15871731 Review.
-
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29. Eur Urol. 2011. PMID: 21726934 Review.
Cited by
-
[Influence of medical BPS treatment on sexual function].Urologe A. 2018 Dec;57(12):1464-1471. doi: 10.1007/s00120-018-0739-7. Urologe A. 2018. PMID: 30046855 Review. German.
-
Green & Sensitive pH-dependent Spectrofluorimetric Assay of Tamsulosin Hydrochloride and Tadalafil in their New Combined Formulation for Benign Prostatic Hyperplasia: Application to Spiked Human Plasma.J Fluoresc. 2022 Jul;32(4):1581-1590. doi: 10.1007/s10895-022-02938-x. Epub 2022 May 16. J Fluoresc. 2022. PMID: 35576092 Free PMC article.
-
Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.Transl Androl Urol. 2019 Oct;8(5):529-539. doi: 10.21037/tau.2019.10.01. Transl Androl Urol. 2019. PMID: 31807429 Free PMC article. Review.
-
Marijuana, Alcohol, and ED: Correlations with LUTS/BPH.Curr Urol Rep. 2021 Feb 8;22(4):21. doi: 10.1007/s11934-020-01031-9. Curr Urol Rep. 2021. PMID: 33554319 Free PMC article. Review.
-
The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors.Cent European J Urol. 2014;67(3):314-8. doi: 10.5173/ceju.2014.03.art20. Epub 2014 Aug 18. Cent European J Urol. 2014. PMID: 25247094 Free PMC article. Review.
References
-
- Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7) Eur Urol. 2003;44:637–649. - PubMed
-
- McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006;97(Suppl. 2):23–28. - PubMed
-
- Melman A, Gindell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 2005;161(1):5–11. - PubMed
-
- Naderi N, Mochtar CA, de la Rosette JJ. Real life practice in the management of benign prostatic hyperplasia. Curr Opin Urol. 2004;14(1):41–44. - PubMed
-
- Dutkiewicz S, Duda W, Duda M. Preliminary study the assessment of sexual function and erectile dysfunction patients with benign prostatic hyperplasia. Polish Sexology. 2010;8(2):55–59.
LinkOut - more resources
Full Text Sources